Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome
Ionis Pharmaceuticals announced the dosing of the first participant in the Phase 1-2 ASCEND study of ION337 for Dravet syndrome. The open-label study will evaluate the safety and tolerability of ION337 in children aged 2 to 12, with dosing potentially occurring every six months using the company's NMA technology.
Key figures
- Drug Name
- ION337
- Phase Of Trial
- Phase 1-2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.